Ticker Details
Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
IPO Date:	April 28, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.88B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.95 | 2.53%
Avg Daily Range (30 D):	$0.57 | 2.16%
Avg Daily Range (90 D):	$0.48 | 1.94%

Institutional Daily Volume
Avg Daily Volume:	.45M
Avg Daily Volume (30 D):	.47M
Avg Daily Volume (90 D):	.53M

Trade Size
Avg Trade Size (Sh.):	95
Avg Trade Size (Sh.) (30 D):	46
Avg Trade Size (Sh.) (90 D):	46

Institutional Trades
Total Institutional Trades:	1,885
Avg Institutional Trade:	$1.79M
Avg Institutional Trade (30 D):	$2.44M
Avg Institutional Trade (90 D):	$2.23M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.51M
Avg Closing Trade (30 D):	$2.48M
Avg Closing Trade (90 D):	$2.22M
Avg Closing Volume:	99.52K

News

May 13, 2026 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: Na

Apr 17, 2026 @ 7:00 PM Zymeworks Presents New Preclinical Data at AACR 20... Source: Zymeworks Inc.

Apr 9, 2026 @ 10:00 AM Zymeworks Announces Additional Leadership Appointm... Source: Na

Apr 1, 2026 @ 10:00 AM Zymeworks Appoints Kristin Stafford as Chief Finan... Source: Na

Mar 30, 2026 @ 10:00 AM Zymeworks Receives U.S. FDA Fast Track Designation... Source: Na

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.37	$-.59	$-.55
Diluted EPS	$-1.37	$-.59	$-.55
Revenue	$81.26M	$2.41M	$2.52M
Gross Profit
Net Income / Loss	$-102.66M	$-44.16M	$-41.21M
Operating Income / Loss	$-114.05M	$-47.12M	$-44.15M
Cost of Revenue
Net Cash Flow	$168.08M	$203.13M	$-23.68M
PE Ratio